Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib versus methotrexate in recurrent/metastatic head and neck squamous cell carcinoma after platinum failure
CTR20140651Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of afatinib, methotrexate in head and neck squamous cell carcinoma (HNSCC), sponsored by Boehringer Ingelheim. Started Jun 2013; status: active.
02
Drugs
afatinibmethotrexate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20140651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140651.